BioTelemetry (NSDQ:BEAT) said today it will pay $7 million in cash to pick up Telcare Medical Supply, which it said was the 1st company to receive FDA clearance for a cellular-enabled blood glucose monitoring system. The deal will include $7 million in cash up front with the potential for an additional $5 million in performance-based earn-outs, […]
BioTelemetry (NSDQ:BEAT) said on Monday it won CE Mark approval in the European Union for its Holter analysis software. The Pennsylvania-based company said the device is usable on a stand-alone basis or with any of its digital holter recorders, and that it expects to market the software under its Millenia brand name. “With the achievement of this […]
Both BioTelemetry (NSDQ:BEAT) and digital health startup InfoBionic celebrated victory in their patent fight with each other over wireless cardiac monitoring technology. But the battle is far from over. Pennsylvania-based BioTelemetry disclosed that the Massachusetts District Court stopped InfoBionic from making, using, marketing or selling in the U.S., or importing into the country, any of its […]
BioTelemetry (NSDQ:BEAT) said yesterday that it closed its $15.5 million acquisition of clinical trial imaging provider VirtualScopics (NSDQ:VSCP), approximately 6 weeks after the deal was 1st announced. The all-cash buyout of Rochester, N.Y.-based VirtualScopics included a $4.05-per-share tender for roughly 3 million VirtualScopics shares. BioTelemetry also offered $336.50 per share for the company’s Series A and […]
BioTelemetry (NSDQ:BEAT) said last week that it agreed to pay about $15.5 million to acquire clinical trial imaging provider VirtualScopics (NSDQ:VSCP) with an all-cash tender offer. Terms of the deal for Rochester, N.Y.-based VirtualScopics include a $4.05-per-share tender for roughly 3 million VSCP shares. BioTelemetry, which is based in Malvern, Pa., is also due to offer $336.30 per share for VirtualScopics’ […]
UPDATED April 3, 2015, with comment from BioTelemetry.
BioTelemetry Inc. agreed to fork over $6.4 million to settle federal charges that its CardioNet subsidiary overbilled Medicare for unnecessary outpatient services.